For the quarter ending 2026-03-31, MLTX has $400,374K in assets. $146,350K in debts. $298,490K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 298,490 | 334,517 | 350,736 | 306,681 |
| Short-term marketable debt securities | 59,431 | 59,451 | 29,743 | 118,402 |
| Other receivables | 5,763 | 4,869 | 4,022 | 3,409 |
| Prepaid expenses | 32,957 | 22,857 | 26,714 | 26,989 |
| Total current assets | 396,641 | 421,694 | 411,215 | 455,481 |
| Operating lease right-of-use assets | 1,857 | 1,566 | 1,911 | 2,251 |
| Property and equipment, net | 532 | 577 | 622 | 667 |
| Other non-current assets | 1,344 | 596 | 587 | 1,697 |
| Total non-current assets | 3,733 | 2,739 | 3,120 | 4,615 |
| Total assets | 400,374 | 424,433 | 414,335 | 460,096 |
| Trade and other payables | 23,380 | 29,553 | 25,282 | 17,079 |
| Accrued expenses and other current liabilities | 21,814 | 14,691 | 21,587 | 8,732 |
| Short-term portion of operating lease liabilities | 920 | 1,234 | 1,499 | 1,550 |
| Total current liabilities | 46,114 | 45,478 | 48,368 | 27,361 |
| Long-term debt | 99,018 | 74,100 | 73,741 | 73,381 |
| Long-term portion of operating lease liabilities | 865 | 374 | 486 | 836 |
| Pension liability | 353 | 0 | 549 | 574 |
| Total non-current liabilities | 100,236 | 74,474 | 74,776 | 74,791 |
| Common shares-Common Class C | - | 0 | 0 | 0 |
| Total liabilities | 146,350 | 119,952 | 123,144 | 102,152 |
| Common shares | 7 | 7 | 6 | 6 |
| Additional paid-in capital | 786,313 | 766,781 | 689,108 | 683,962 |
| Accumulated deficit | -532,618 | -462,911 | -400,486 | -330,757 |
| Accumulated other comprehensive income | 322 | 604 | 278 | 520 |
| Total shareholders equity | 254,024 | 304,481 | 288,906 | 353,731 |
| Noncontrolling interests | - | 0 | 2,285 | 4,213 |
| Total equity | - | 304,481 | 291,191 | 357,944 |
| Total liabilities and shareholders' equity | 400,374 | 424,433 | 414,335 | 460,096 |
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)